trial · primary record
Pembrolizumab
Non-small Cell Lung Cancer Stage IB
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Major pathologic response (MPR) rate by central review |
| Registry ID | NCT04040361 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:30.103Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04040361
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound